Non Subscriber: Buy This Issue

Opioid Overdose & Naloxone
Rescue Kits

Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for the issue, return to this Introduction page and click the "Take the Test" button. The Introduction page will remain open after you open this issue.
You may need to re-size or close the issue in order to see the Introduction page.

Overview

Fatal drug overdoses

, due to both illicit and prescription drug use, have become epidemic in the United States (US). The rate exceeds that of deaths from motor vehicle accidents, largely due to the increase in

prescription opioid overdoses

. In 2013, about 16,000 deaths occurred from prescription opioid overdoses, accounting for more than half of all prescription drug overdose deaths. Multiple substances (eg, alcohol, benzodiazepines, and other sedating drugs) often contribute to these overdose deaths. Many opioid overdoses occur in patients with legitimate opioid prescriptions who have identifiable risk factors.

This issue provides historical background about the opioid overdose epidemic, followed by information about naloxone – a mu opioid receptor antagonist that is indicated for the treatment of respiratory and/or central nervous system (CNS) depression due to opioid overdose. The information includes a discussion of emerging

Opioid Education and Naloxone Distribution (OEND)

programs which enable pharmacists to identify overdose risks; educate prescribers, patients, and family members or caregivers about overdose risks; and dispense, distribute, or even prescribe naloxone kits for bystander administration in the event of an opioid overdose.

Community practitioners, including pharmacists, are in an opportune position to identify at-risk patients, remind prescribers about individual patient's risks, provide OEND to patients and their family members, friends, and caregivers; and, potentially, reduce deaths associated with opioid medications...

Details

Publication Date: 09/20/2015
Expiration Date: 09/20/2018
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based

This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.

Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.

Authors

Chris Stock, PharmD, BCPP is a clinical pharmacy specialist and researcher at the George E Wahlen VA Medical Center in Salt Lake City. He is also Adjunct Professor at the University of Utah. He has specialized in treatment of substance use disorders and related research. For the past 3 years, he has advocated within the VA and in the State of Utah for expanded naloxone access and pharmacists’ involvement in OEND.

Melissa Joy Brewster, PharmD, BCPS is a Clinical Pharmacy Specialist in Mental Health at the George E Wahlen VA Medical Center in Salt Lake City, UT.

Disclosure Statement

Dr. Chris Stock and Dr. Melissa Brewster report no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Target Audience

This accredited program is targeted to pharmacists and nurses.

Goals & Objectives

At the conclusion of this program, participants will be able to:

    1. Describe how increased opioid prescribing has led to an epidemic of overdose deaths. Discuss steps that are being taken to confront this epidemic, including Overdose Education and Naloxone Distribution (OEND).
    2. Describe the indications, contraindications, routes of administration, doses, and adverse effects of naloxone.
    3. Identify individuals at increased risk for opioid overdose. Teach patients and their family members/friends how to recognize and respond to an opioid overdose, and how to administer naloxone.

Accreditation Statements

The Rx Consultant is a publication of Continuing Education Network, Inc.

Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a provider of continuing pharmacy education.

Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.

ACPE Universal Activity Number: 0428-0000-15-009-H01-P


Exam & Credit Statement Procedures

Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and program evaluation.

Editorial and Review Board

Chief Editor and CE Administrator


Terry M. Baker, PharmD

Managing Editor


Tracy Farnen, PharmD

Associate Editors


James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Kaiser Permanente
Oakland, CA

Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA

Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA

Consultant Pharmacist
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA

Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA

Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System

Adjunct Clinical Professor
College of Pharmacy
Touro University
Vallejo, CA

Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Stockton, CA

Visiting Associate Professor and Lecturer
Nursing School
Samuel Merritt University
Oakland, CA

Pamela Mausner, MD

Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Detroit, MI

Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Detroit, MI

Senior Editorial Advisor


Gerard Hatheway, PharmD, PhD

Editorial Advisors


Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD

Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners


Emily K.
Meuleman, RN, C, MS

About the Rx Consultant

The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to educate patients about drugs and manage drug therapy. The reader is responsible for confirming the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.

Technical Specifications

Hardware requirements

Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.

Software requirements

Browser that supports TLS 1.1 + and PDF files.

This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.

Adobe Acrobat Reader is recommended, and is required for some browsers.

Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.

Internet Connectivity

Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)

Contact Us

Exam Processing Inquiries

The Rx Consultant
rxmail@rxconsultant.com
1-800-798-3353

Educational Content Inquiries

The Rx Consultant
editor@rxconsultant.com
1-800-798-3353

Non Subscriber: Buy This Issue